SU
Surgical Science Sweden AB
SUSRF · OTC
$5.20 +0.00% (+$0.00)
Market Cap 2.61B kr
P/E Ratio 28.06x
Div. Yield -
ROE 2.12%
Bulios Fair Price
$3.11
40.2% downside
Current Price
$5.2
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SUSRF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
64 /100
Fair EV/EBITDA 9.21x
P/S 2.56x
P/B 0.58x
Growth
22 /100
Declining Rev. growth 7.24%
FCF growth 10.55%
Book val. growth 0.20%
Profitability
69 /100
Strong Net margin 9.11%
Op. margin 13.76%
FCF margin 10.38%
Quality
11 /100
Poor ROE 2.12%
ROA 1.88%
Asset turnover 0.21x
Debt
100 /100
Low Current ratio 4.24x
Int. coverage 29.91x
Net debt/EBITDA -3.06x
Stability
84 /100
Stable Rev. volatility 6.34%
EPS volatility 41.27%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SUSRF
Online
Sector
Healthcare
Industry
Medical - Healthcare Information Services
CEO
Tom Englund
Employees
313
Headquarters
Gothenburg
Upcoming events
12 NOV
Earnings
Upcoming earnings report